| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| cannabidiol | arylalkylamine n-acetyltransferase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | acetyl-coa acetyltransferase, mitochondrial | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | adenosine receptor a1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | activator |
| cannabidiol | voltage-dependent t-type calcium channel subunit alpha-1g | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | voltage-dependent t-type calcium channel subunit alpha-1h | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | voltage-dependent t-type calcium channel subunit alpha-1i | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | catalase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | neuronal acetylcholine receptor subunit alpha-7 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | cannabinoid receptor 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
0.98 | approved,investigational | antagonist,modulator,allosteric modulator |
| cannabidiol | cannabinoid receptor 1 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
0.98 | approved,investigational | antagonist,modulator |
| cannabidiol | cannabinoid receptor 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | antagonist |
| cannabidiol | steroid 17-alpha-hydroxylase/17,20 lyase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | cytochrome p450 1a2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | cytochrome p450 1b1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | cytochrome p450 2d6 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | cytochrome p450 3a5 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | cytochrome p450 3a7 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | glycine receptor (alpha-1/beta) | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | allosteric modulator |
| cannabidiol | glycine receptor subunit alpha-1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | glycine receptor subunit alpha-3 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | potentiator |
| cannabidiol | glycine receptor (alpha-1/beta) | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | allosteric modulator |
| cannabidiol | g-protein coupled receptor 12 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inverse agonist |
| cannabidiol | n-arachidonyl glycine receptor | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
8.49 | approved,investigational | agonist |
| cannabidiol | g-protein coupled receptor 55 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
2.25 | approved,investigational | antagonist |
| cannabidiol | glutathione peroxidase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | stimulator |
| cannabidiol | glutathione reductase, mitochondrial | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | stimulator |
| cannabidiol | 3-hydroxy-3-methylglutaryl-coenzyme a reductase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | stimulator |
| cannabidiol | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | agonist |
| cannabidiol | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | agonist |
| cannabidiol | 5-hydroxytryptamine receptor 3a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | antagonist |
| cannabidiol | indoleamine 2,3-dioxygenase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | n-acylethanolamine-hydrolyzing acid amidase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | nad(p)h dehydrogenase [quinone] 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | delta-type opioid receptor | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | mu-type opioid receptor | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| cannabidiol | peroxisome proliferator-activated receptor gamma | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | activator |
| cannabidiol | prostaglandin g/h synthase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | prostaglandin g/h synthase 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | superoxide dismutase [cu-zn] | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | inhibitor |
| cannabidiol | transient receptor potential cation channel subfamily a member 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | agonist |
| cannabidiol | transient receptor potential cation channel subfamily m member 8 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
3.18 | approved,investigational | blocker |
| cannabidiol | transient receptor potential cation channel subfamily v member 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | activator |
| cannabidiol | transient receptor potential cation channel subfamily v member 2 | small molecule | NA | drugbank , DGIDB | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
19.1 | approved,investigational | activator |
| cannabidiol | transient receptor potential cation channel subfamily v member 3 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | activator |
| cannabidiol | transient receptor potential cation channel subfamily v member 4 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | activator |
| cannabidiol | voltage-dependent anion-selective channel protein 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Muscle Spasticity[MeSHID:D009128] Compliance behavior[MeSHID:D010349] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] West Syndrome[MeSHID:D013036] Epilepsy[MeSHID:D004827] Syndrome[MeSHID:D013577] Infantile Severe Myoclonic Epilepsy[MeSHID:D004831] |
NA | approved,investigational | unknown |
| click here to return to the previous page | ||||||||